SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):104P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dadachova, E.
Right arrow Articles by Casadevall, A.
PubMed
Right arrow Articles by Dadachova, E.
Right arrow Articles by Casadevall, A.

Oncology-Basic Science: Basic Science

New Targets

Viral antigens as novel targets for radioimmunotherapy of viral cancers

Ekaterina Dadachova1, Xing Guo Wang1, Ekaterina Revskaya1, Ruth Bryan1 and Arturo Casadevall1

1 Albert Einstein College of Medicine, Bronx, New York


Formula


Formula

412

Objectives: Viral cancers have a major impact on health worldwide and the associations of hepatitis B and C infections with hepatocellular carcinoma (HCC) and of human papilloma virus (HPV) infection with cervical cancer (CC) have been firmly established. There is an urgent need to find new approaches to treatment and prevention of viral cancers. Viral antigens have not been previously considered as targets for treatment of viral cancers. We hypothesized that it was possible to treat experimental HPV16-associated CC and Hepatitis B-associated HCC by targeting viral antigens with radiolabeled antibodies to viral antigens.

Methods: We evaluated HPV-16 associated oncoprotein E6 and Hepatitis B-associated HBx viral protein as potential targets for RIT of CC and HCC, respectively, by performing Western blot and immunofluorescence of CasKi human CC cells and Hep 3B2.1-7 human HCC cells. The ability of 188Re-labeled mAbs to E6 and HBx viral proteins to target viral proteins in vivo for radioimmunotherapy purposes was evaluated in experimental CC and HCC tumors in nude mice.

Results: Treatment of experimental CC and HCC tumors with 188Re-labeled mAbs to E6 and HBx viral proteins, respectively, resulted in significant and dose-dependent retardation of tumor growth in comparison with untreated mice or mice treated with unlabeled antibodies.

Conclusions: This strategy is fundamentally different from the prior uses of radioimmunotherapy in oncology, which targeted "self" human antigens and promises exclusive specificity and minimal toxicity of treatment.

Research Support: NIH, CFAR, AECOM Cancer Center





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dadachova, E.
Right arrow Articles by Casadevall, A.
PubMed
Right arrow Articles by Dadachova, E.
Right arrow Articles by Casadevall, A.